MOUD For Pregnant Women With OUD Associated With Higher Six-Month Treatment Retention Rates

For pregnant women in the U.S. with opioid use disorder (OUD), outpatient treatment episodes with medications for opioid use disorder (MOUD) were associated with 86% higher odds of six-month treatment retention compared to treatment episodes without MOUD. A recent analysis of 2021 data determined that this translated to a 14.2 percentage point higher adjusted probability of six-month retention among treatment episodes with MOUD (43.1%) compared to those without it (28.9%).

The cross-sectional study analyzed 29,981 outpatient treatment episodes from a cohort of pregnant consumers receiving MOUD between 2015 and 2021, including methadone . . .